Get the Stockscreener App
9.44
7.15%
0.63
Turn Therapeutics Inc stock is traded at $9.44, with a volume of 163.47K.
It is up +7.15% in the last 24 hours and up +70.71% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
See More
Previous Close:
$8.81
Open:
$8.82
24h Volume:
163.47K
Relative Volume:
2.81
Market Cap:
$281.20M
Revenue:
-
Net Income/Loss:
$-1.77M
P/E Ratio:
-63.48
EPS:
-0.1487
Net Cash Flow:
$-1.46M
1W Performance:
+32.58%
1M Performance:
+70.71%
6M Performance:
+104.33%
1Y Performance:
+0.00%
1-Day Range:
$8.81
$10.00
1-Week Range:
$7.10
$11.69
52-Week Range:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
9.44 | 281.20M | 0 | -1.77M | -1.46M | -0.1487 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Initiated | D. Boral Capital | Buy |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics Inc.Common Stock (TTRX) Stock Price, News, Quote & History - FinancialContent
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout - sharewise.com
Turn Therapeutics’ stock jumps on AD data and trial expansion - MSN
Turn Therapeutics Reaches US$229m Market Cap Benefiting Insider Stock Buying - Moomoo
Turn Therapeutics (TTRX) Study update Summary - Quartr
TTRX: GX-03 phase II interim data show robust efficacy and safety, with stage two now optimized - TradingView
TTRX: GX-03 phase II interim data show strong efficacy and safety, with phase III targeted for mid-2027 - TradingView
Why Is Turn Therapeutics Stock Trading Higher Today? - Benzinga
AD Pipeline Watch: Turn Therapeutics Expands Phase 2 AD Trial After GX-03 Shows Broad Efficacy in Interim Analysis - The Dermatology Digest
TTRX: GX-03 demonstrates robust efficacy and safety in Phase 2 atopic dermatitis interim analysis - TradingView
TTRX: GX-03 showed robust efficacy in atopic dermatitis, leading to an expanded Phase 2 trial design - TradingView
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - BioSpace
Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com - Investing.com UK
Turn Therapeutics stock rises on expanded dermatitis trial - Investing.com
Turn Therapeutics expands phase 2 atopic dermatitis trial - Investing.com
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis - marketscreener.com
Turn Therapeutics expands phase 2 atopic dermatitis trial By Investing.com - Investing.com Nigeria
EDGAR Filing Documents for 0001213900-26-075757 - SEC.gov
Turn Therapeutics finalizes expanded Stage 2 design for GX-03 Phase 2 in atopic dermatitis - TradingView
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Turn Therapeutics (TTRX) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - BioSpace
Turn Therapeutics Gains Ahead of Release of Dermatitis Drug Data - Moomoo
Stocks to Watch: Rivian, Turn Therapeutics, Globavend - Moomoo
If You Invested $1,000 in Turn Therapeutics Inc (TTRX) - Stock Titan
Turn Therapeutics Company Profile & Introduction - Moomoo
TTRX Q1 2026 Earnings: Narrow EPS Miss as Pre-Revenue Biotech Focuses on Pipeline ProgressEarnings Revision Report - dars.gov.et
TTRXTurn Therapeutics Inc Volatility & Greeks - Finviz
Turn Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Turn Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$217m - Sahm
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - The National Law Review
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Turn Therapeutics Inc.(NasdaqGM: TTRX) added to Russell 3000E Growth Benchmark - marketscreener.com
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Turn Therapeutics Inc.(NasdaqGM: TTRX) added to Russell Microcap Index - marketscreener.com
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics (TTRX) Short Interest & Short Float | Updated Jun 2026 $TTRX - MarketBeat
Turn Therapeutics Inc. Actuals & Estimates (NASDAQ:TTRX) - TradingView
TTRX Q1 2026 Earnings: Narrow Miss on EPS as Stock RisesInvestor Earnings Call - dars.gov.et
Strength seen in Intellia Therapeutics (NTLA): Can its 23.2% jump turn into more strength? - MSN
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Ord Shs (TTRX) Institutional Confidence - TradingKey
Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads - StocksToTrade
Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo Finance
Number of shareholders of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Slight EPS Miss Amid Pre-Revenue Stage; Shares Rise - newsline.com
First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Turn Therapeutics Inc Stock (TTRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Turn Therapeutics Inc Stock (TTRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):